Effect of Different Chemotherapy Regimens on the Development of Drug-Induced Liver Disease in Patients with Chronic Lymphocytic Leukemia


chronic lymphocytic leukemia
drug-induced liver disease

How to Cite

Hrydzhuk, T. I., & Serediuk, N. M. (2014). Effect of Different Chemotherapy Regimens on the Development of Drug-Induced Liver Disease in Patients with Chronic Lymphocytic Leukemia. Galician Medical Journal, 21(3), 75-79. Retrieved from https://ifnmujournal.com/gmj/article/view/239


The objective of the research was to establish the frequency and variability of drug-induced liver disease (DILD) in patients with chronic lymphocytic leukemia (CLL) according to the chemotherapy (CT) regimens. It was proved an adverse effect of investigated chemotherapeutic agents on the dynamics of functional state of the liver and heterogeneity of peculiarities of drug-induced lesions of hepatocytes based on the type of drug applied due to cytostatic treatment was established. Type of drug-induced liver disease (DILD) was determined depending on the degree of increase of alanine aminotransferase and alkaline phosphatase. It was established that usage of leukeran as the main drug in the chemotherapy of chronic lymphocytic leukemia led to holestastatic syndrome (70.27%) that caused growth of serum bilirubin and alkaline phosphatase. The application of the FC scheme for the CLL treatment led to formation of the cytolysis syndrome (81.58%) with increased plasma concentration of transaminases. The use of the CHOP contributed to such signs as cholestatic cytolytic syndromes (65%). It was established the dependence of the degree of hepatotoxicity on chemotherapy regime and presence of risk factors. The presence of two or more risk factors had unfavorable prognosis regarding the degree of hepatotoxicity. 



Babak O. Ya. Drug-induced liver lesions: theory and practice questions. Liky Ukraiiny. 2008; 2: 96-101.

Ivashkin V.T., Nepomnyaschikh G.I., Aydagulova S.V. Drug-induced liver injuries. Rossysky zhurnal gastroenterologii, gepatologii, koloproktologii.. 2009; 2: 20-29.

Klyaritskaya I.L., Maksimova E.V. Hepatotoxicity in Oncology. Novosti meditsiny i farmatsii. 2010; 323: 30-36.

Kuznetsova O.V., Rybin A.I., Dubinina V.G. Hepatotoxicity of dіfferent chemotherapeutic schemes in treatment of female reproductive system tumors. Arkhiv klinichnoii ta eksperymentalnoii medytsyny. 2013; 22(1): 60-64.

Larionova V.B. Hepatotoxicity of drugs in oncologic patients. Vestnik intensivnoy terapii. 2004; 3: 1-10.

Lopatkina T.N., Burnevych E.Z. Drug-induced liver lesions. Vrach. 2003; 12: 18-20.

Rakov A. Application of hepatoprotective therapy in treatment of chronic diseases and liver lesions. M. 2006; 22.

Marino G., Limmerman H.J. Management of drug-induced liver disease. Cur. Gastro. Reports. 2007; 3: 38-48.

Navarro V.J., Senior J.R. Drug-Related Hepatotoxicity. N. Engl. J. Med. 2006; 354 (7): 731-739.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.